Ontology highlight
ABSTRACT: Background
The efficacy of ertugliflozin, a sodium-glucose cotransporter 2 inhibitor, for glycemic and blood pressure (BP) control has been demonstrated in phase 3 studies. To further evaluate the effects of ertugliflozin on BP and other hemodynamic parameters, an analysis was conducted on the pooled patient populations from these studies.Methods
This was a post hoc analysis of data from three phase 3 studies (NCT01958671, NCT02033889, and NCT02036515) of adults with type 2 diabetes mellitus who received placebo, ertugliflozin 5 mg, or ertugliflozin 15 mg. Outcomes at 26 weeks were analyzed for the pooled population and according to relevant baseline factors, including BP.Results
Of the 1544 patients included (placebo, n = 515; ertugliflozin 5 mg, n = 519; ertuglifl
SUBMITTER: Liu J
PROVIDER: S-EPMC6503446 | biostudies-literature | 2019 May
REPOSITORIES: biostudies-literature